 |
|
Promising Drug Combination May Help Those with Ocular Melanoma that has Spread
September 05, 2007DURHAM, N.C. -- A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers.
The drugs -- decitabine, which can turn on certain genes in cancer cells, and interferon gamma, an immune system protein -- may work together to cause cancer cell death.
"Metastatic uveal melanoma, or melanoma that originates in the eye and spreads to other parts of the body, has been very difficult to treat, in fact there have been no effective therapies to date," said Jared Gollob, M.D., a medical oncologist at Duke and lead investigator on the study. "This study could lead to a very promising new therapy for patients who previously had very little hope."
The researchers published their findings in the September 1, 2007 issue of the journal Clinical Cancer Research. The study was funded by the National Institutes of Health.
This pre-clinical study came on the heels of previous lab work examining proteins called interferons, which originate from immune system cells. These proteins were shown to boost immune function and directly affect melanoma cells, inhibiting their growth and accelerating their death, Gollob said.
"We also knew that a drug called decitibine could turn on genes that had been turned off in cancer cells, so we speculated that if we combined decitabine and interferon gamma, we might see heightened cell death, and that's exactly what happened," Gollob said. Decitabine may turn on a certain gene, called S100A2, that is, in turn, able to increase the sensitivity of cancer cells to interferon gamma, he said.
Researchers used human cell lines, derived from patients who had been diagnosed with uveal melanoma, for this study. The next step will be a clinical study looking at the effectiveness of this drug combination in human subjects, Gollob said.
Uveal melanoma affects about 5,000 to 10,000 people each year in the United States. Unlike its counterpart on the skin, there are no known risk factors, Gollob said.
"There are really no truly effective treatments for this devastating disease," he said. "So this study really is a promising step toward finding a therapy that can really help these patients."
Uveal melanoma originates in the colored part of the eye, and symptoms include changes in vision, such as blurriness. If found early, it can be treated with radiation or with removal of the eye. When it spreads, uveal melanoma is typically unresponsive to standard treatment regimens, such as chemotherapy, Gollob said. Life expectancy once the disease has spread is about six to ten months, on average, he said.
Catherine Sciambi of Duke was co-author on the study.
Duke University Medical Center
The researchers published their findings in the September 1, 2007 issue of the journal Clinical Cancer Research. The study was funded by the National Institutes of Health.
This pre-clinical study came on the heels of previous lab work examining proteins called interferons, which originate from immune system cells. These proteins were shown to boost immune function and directly affect melanoma cells, inhibiting their growth and accelerating their death, Gollob said.
"We also knew that a drug called decitibine could turn on genes that had been turned off in cancer cells, so we speculated that if we combined decitabine and interferon gamma, we might see heightened cell death, and that's exactly what happened," Gollob said. Decitabine may turn on a certain gene, called S100A2, that is, in turn, able to increase the sensitivity of cancer cells to interferon gamma, he said.
Researchers used human cell lines, derived from patients who had been diagnosed with uveal melanoma, for this study. The next step will be a clinical study looking at the effectiveness of this drug combination in human subjects, Gollob said.
Uveal melanoma affects about 5,000 to 10,000 people each year in the United States. Unlike its counterpart on the skin, there are no known risk factors, Gollob said.
"There are really no truly effective treatments for this devastating disease," he said. "So this study really is a promising step toward finding a therapy that can really help these patients."
Uveal melanoma originates in the colored part of the eye, and symptoms include changes in vision, such as blurriness. If found early, it can be treated with radiation or with removal of the eye. When it spreads, uveal melanoma is typically unresponsive to standard treatment regimens, such as chemotherapy, Gollob said. Life expectancy once the disease has spread is about six to ten months, on average, he said.
Catherine Sciambi of Duke was co-author on the study.
Duke University Medical Center
Ocular Melanoma Current Events and Ocular Melanoma News RSSHSP90: New point of view on melanoma of the eye, at the MUHC
Ocular melanoma is rarely detected before it has grown large enough to impair vision or to metastasize. This makes it a particularly challenging disease to fight, especially since chemotherapy is not very effective.
New genetic test predicts risk of metastasis in patients with deadly eye cancer
Imagine being diagnosed with eye cancer - but your doctor can't tell whether you have the aggressive type that will swiftly spread, causing blindness and death in as early as a year.
Molecular markers signal early metastases from ocular melanoma
Patients with melanoma of the eye are at risk for liver metastases, which are often not detected until they have turned into large, lethal tumors.
Test can predict spread of eye cancer to liver
Scientists at Washington University School of Medicine in St. Louis have developed a method to predict whether melanoma of the eye will spread to the liver, where it quickly turns deadly.
Radiation therapy can help spare vision in patients with melanoma of the eye
Treating a rare form of eye cancer with radiation therapy can spare patients from significant vision loss.
New epidemiological review finds no causal association between the use of cellular phones and cancer
The Swedish Radiation Protection Authority has engaged two internationally well-known epidemiologists to review published epidemiological studies on the relationship between the use of cellular telephones and cancer risk. They are Dr. John D. Boice, Jr. and Dr. Joseph K. McLaughlin from the International Epidemiology Institute, USA. In their review, no consistent evidence was observed for increased risk of brain cancer, meningioma, acoustic neurinoma, ocular melanoma, or salivary gland cancer, examined over a wide range of exposure measures, including type of phone, duration of use, frequency of use, total cumulative hours of use, tumor location and laterality (concurrence of tumor location
More Ocular Melanoma Current Events and Ocular Melanoma News Articles
| Keep an eye out for ocular and periocular melanoma.(Dermatology): An article from: Internal Medicine News by Doug Brunk This digital document is an article from Internal Medicine News, published by International Medical News Group on March 1, 2005. The length of the article is 464 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
 | Finding Noel: A Novel by Richard Paul Evans When I wrote my first novel, The Christmas Box, I never imagined it would become an international bestseller. It was a story for my two (then) little girls. But as I wrote, I realized that it was also for my mother -- to ease her pain over losing a child. My mother was my staunchest supporter and my biggest fan. A receptionist at a doctor's office, she would sell my book (sometimes by the case!)... |
 | Radiotherapy of Intraocular and Orbital Tumors (Medical Radiology / Radiation Oncology) This 2nd edition provides up-to-date information on the diagnosis and treatment of cancers of the eye and orbit. The 1st edition has been significantly revised. The most recent data with respect to retinoblastoma, rhabdomyosarcoma, and melanoma are included, and there are a number of chapters by new contributors, lending this edition a more broadly based, international character. The presenting... |
| © 2008 BrightSurf.com |